Dear All, Continuing with the theme of socio-economic inequality and AMR that we discussed in prior newsletters (31 Jan 2022, “RFP: Support For Creating Antimicrobial Stewardship Centers Of Excellence” and 26 Oct 2021, “$50-100k Grants To Address Socioeconomic Outcome Disparities Due To AMR-Related Factors”), we today have an RFP on gender and AMR from the
Dear All, First up, we have an update to WHO’s review of the clinical antibacterial pipeline. The review by Butler et al. in AAC (and for transparency, know that I am a co-author) covers both traditional and non-traditional products. It found that as of 30 June 2021: There were 76 antibacterial agents in clinical development
Dear All, Our colleagues at FDA are planning some serious AMR-related research during 2021-22 with the following fellowships and RFPs. Extended details are available via the links — you can also find brief summaries below my signature or via FDA’s research webpage. Wow! FDA Fellowship #1: A study of ordinal endpoints for antibiotic trials using
Dear All: Happy New Year! I hope everyone was able to take a least a brief break over the holidays. Two things for today. First, there are two meetings in January and one in February that have just popped onto my radar. See the meetings calendar for a pair of Keystone Symposia on the microbiome,
Dear All, The Wellcome Trust Drug-Resistant Infections team wants to understand what researchers in academia and SMEs need to enable them to be better able to make progress with their early antibiotic discovery projects. Although some programs are now in place (e.g., the accelerator support provided by CARB-X), what are the remaining barriers? To help
Dear All, WHO have been thinking about the threat of resistant fungi as well as resistant bacteria. An initial discussion by a small working group on approaches to priority fungal pathogens (April 2020, here’s the link to the report) concluded that Candida auris; azole-resistant Candida spp., azole-resistant Aspergillus fumigatus, Cryptococcus neoformans (& C. gattii), Pneumocystis jirovecii, Mucorales, and potentially Histoplasmosis were
Dear All: Two things of note this afternoon… First, the previously noted BARDA RFP to acquire biothreat antibiotics is now posted here with submissions accepted through 21 June 2019: “Under this RFP, BARDA plans to support the procurement of antibiotic(s), which will either be delivered to the ASPR/SNS or maintained as VMI, using Project BioShield (PBS) funds. “PBS funds will also support
Dear All: Ready, set, (get ready to) go! I just today learned of this really important US government pre-solicitation notice (lightly reformatted excerpt follows, see here for the whole thing): “The Government seeks an FDA-approved antibiotic(s) for a biothreat indication (Y. pestis, B. anthracis, F. tularensis, B. mallei and/or B. pseudomallei) for delivery to the Office of the Assistant Secretary for Preparedness and Response
Dear All: Just released today is an RFP (see text just below my signature) to develop a business plan for the design, funding, and implementation of a sustainable clinical trial network for developing new antibacterial agents. The core of this idea emerged in early 2016 based on debates about the potential value of a network focused on a
Dear All: I have just learned that Wellcome Trust is seeking applications to address an RFP (Request for Proposal) for two pieces of work designed to support the recently created UN Interagency Coordination Group (IACG) on AMR. RFP #1 is for a review of the roles, responsibilities and remit of UN organisations in relation to AMR, identifying
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust